-
SIBCS 2024 | A Sneak Peek at Key Updates in the 2025 Edition of the “CBCS Little Red Book” from Top Experts
The expert voting on key issues for the 2025 edition of the Guidelines and Standards for Breast Cancer Diagnosis and Treatment (Essential Version), also known as the CBCS Little Red Book, organized by the Chinese Anti-Cancer Association and the Chinese Medical Association’s Oncology Branch, has concluded. The new version is on the horizon! Oncology Frontier…
-
Dr.Hong You and Dr.Wei Chen’s Team Proliferative T Cell Subpopulations in the Liver Promote Fibrosis Reversal in CHB Patients After Antiviral Therapy
Research Background and Objectives CHB liver fibrosis is a pathological condition resulting from imbalanced extracellular matrix deposition due to HBV-induced liver damage and repair. This condition can progress to cirrhosis…
-
AASLD’s Chinese Impact: Dr. Liang Peng’s Team Achieves Multiple Research Milestones in Chronic Hepatitis B and Related Liver Failure
Study 1: Personalized Nutritional Support for HBV-ACLF Patients at Nutritional Risk: Preliminary Findings from a Randomized Controlled Trial Authors: Zhipeng Li, Peipei Wang, Wenxiong Xu, Chan Xie, Liang Peng Malnutrition…
-
AASLD 2024 | Nadege Pelletier: Exploring new hope for innovative immunotherapy for chronic hepatitis B
Hepatology Digest: Thank you for joining us. Could you start by introducing yourself and sharing the focus of Barinthus Biotherapeutics? Nadege Pelletier: Of course, thank you. My name is Nadege…
-
Dr. Hua Zhong and Dr. Baohui Han: Docetaxel Combined with Plinabulin in Second-Line Treatment for Mutation-Negative Advanced NSCLC Patients
Modern advancements in oncology have introduced various breakthrough treatment options for lung cancer, which is now one of the most rapidly evolving solid tumors. To help clinicians stay updated on key advancements in this field, Oncology Frontier has partnered with Dr. Hua Zhong and Dr. Baohui Han of the Department of Respiratory and Critical Care…
-
Dr. Yige Bao: Perioperative Personalized Treatment of UTUC Based on ADC Drugs and the West China Experience
Upper tract urothelial carcinoma (UTUC), encompassing renal pelvic and ureteral cancers, is relatively rare, with unique characteristics in the Chinese population, such as distinct disease features and molecular biology profiles. The 8th West China Uro-Oncology Tianfu Academic Conference, recently held in Chengdu, provided a platform to discuss how to better address the challenges in UTUC…
-
The 8th West China Uro-Oncology Tianfu Academic Conference丨Dr. Hongzhen Li: Advances in Radiotherapy for Urothelial Carcinoma
Urothelial carcinoma (UC) is one of the most common malignant tumors of the urinary system, encompassing bladder cancer, renal pelvic cancer, and ureteral cancer. Radiotherapy, as a critical treatment modality for tumors, has gained prominence in the comprehensive treatment of UC, offering hope for improved survival outcomes. During the 8th West China Urologic Oncology Academic…
-
2024 WAAW丨Dr. Pengfei Shen: Why Urinary Tract Infections Trouble Women？
The third week of every November marks World Antimicrobial Awareness Week (WAAW). This year, WAAW adopts the theme: “Educate, Advocate, Act,” aiming to raise public awareness about antimicrobial drugs, advocate for their appropriate use, and encourage action to combat antimicrobial resistance (AMR). In response to this call, Oncology Frontier invited Dr. Pengfei Shen from West China Hospital of Sichuan University to…
Connecting Medical Expertise through Media